Xuanzhu Biopharmaceutical Co., Ltd. clinical trials
A subsidiary of Sihuan Pharmaceutical Holdings Group Ltd.
The registry lists 24 studies whose lead sponsor is Xuanzhu Biopharmaceutical Co., Ltd.. 11 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 26, 2026.
- 24studies on the registry
- 11open to participants now
- 5phase 3 studies under way
- 2reach primary completion within a year
What it is testing
The drugs Xuanzhu Biopharmaceutical Co., Ltd.’s studies test, most open studies first — 4 drugs with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
- ALK/ROS1 Inhibitor XZP-36211 in phase 32 open · 6
- Bireociclib2 in phase 30 open · 4
- 0 open · 1
- 0 open · 1
Coming up
2 of Xuanzhu Biopharmaceutical Co., Ltd.’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 1DDec
- JJan ’27’27
- 1FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
All 2
Add all 2 to your calendar (.ics) → With an account.
All 24 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 19
- 20
- 721
- 22
- 23
- 24
- 25
- 326
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Xuanzhu Biopharmaceutical Co., Ltd.24 studies
Something wrong with this grouping? Tell us on the Sihuan Pharmaceutical Holdings Group Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 24 of 24. All Sihuan Pharmaceutical Holdings Group Ltd. studies →
- The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter PyloriNot yet recruitingNCT07606833Phase 3
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special PopulationsNot yet recruitingNCT07345689Phase 4
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- Drug-drug Interaction Study of Rifampin and Anaprazole SodiumNot yet recruitingNCT07330531Phase 4
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Clinical Trial of Anaprazole for Treating Reflux Esophagitis.RecruitingNCT07010107Phase 3
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Study of XZB-0004 in Patients With Solid TumorsRecruitingNCT05772455Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Study of KM501 in Patients With Solid TumorsNot yet recruitingNCT05804864Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Study of KM602 in Patients With Advanced Solid TumorsNot yet recruitingNCT05766527Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid TumorsRecruitingNCT04996121Phase 1/2
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLCNot yet recruitingNCT05482087Phase 2
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.Not yet recruitingNCT05320874Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus CrizotinibNot yet recruitingNCT05204628Phase 3
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung CancerCompletedNCT05055232Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast CancerActive, not recruitingNCT05257395Phase 3
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- Food Effect and Mass Balance Study of XZP-3621 TabletsCompletedNCT05034120Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast CancerActive, not recruitingNCT05077449Phase 3
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in HumanStatus unknownNCT05836805Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDSStatus unknownNCT05740917Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Study of Anaprazole Sodium Enteric-coated Tablets in the Treatment of Reflux EsophagitisStatus unknownNCT05604261Phase 2
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- Drug-drug Interaction Study of XZP-3621 TabletStatus unknownNCT05586568Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Clinical Trial of XZP-3287 for Material BalanceStatus unknownNCT05478109Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Clinical Trial of XZP-6019 Tablets in Healthy SubjectsStatus unknownNCT05063968Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- Effect of Food on the Pharmacokinetics of XZP-3287 in Healthy SubjectsStatus unknownNCT04951765Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- Effect of Clarithromycin and Rifampicin on the Pharmacokinetics of XZP-3287 in Healthy SubjectsStatus unknownNCT04951713Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.
- A Phase I Clinical Trial of XZP-5610 Tablets in Healthy SubjectsStatus unknownNCT04913090Phase 1
Sponsor listed in the registry: Xuanzhu Biopharmaceutical Co., Ltd.